July 3rd 2025
Here’s a look back at notable news between April and June 2025.
July 2nd 2025
The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
July 1st 2025
The combination demonstrated a 6-month radiographic progression-free survival of 66%.
A recap of the FDA submissions and regulatory decisions in urology from June 2025.
June 30th 2025
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
FDA news recap in urology for Q2 2025
da Vinci 5 Surgical System approved in Europe
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC